Keyphrases
Retrospective Analysis
100%
Combination Therapy
100%
Bevacizumab
100%
Epithelial Ovarian Carcinoma
100%
Platinum-refractory
100%
Ovarian Cancer
66%
Partial Response
66%
Measurable Disease
66%
Stable Disease
66%
Heavily Pretreated
66%
Intestinal Perforation
66%
Response Rate
33%
Median Time
33%
Progressive Disease
33%
Heavily Pretreated Patients
33%
5-fluorouracil (5-FU)
33%
Best Response
33%
Cyclophosphamide
33%
Carbohydrate Antigen 125 (CA125)
33%
Cytotoxic Chemotherapy
33%
Time to Progression
33%
Cytotoxic Agents
33%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
33%
Docetaxel
33%
Combination Regimen
33%
Pegylated Liposomal Doxorubicin
33%
Bevacizumab Therapy
33%
Chylous Ascites
33%
Progression-free Interval
33%
Medicine and Dentistry
Combination Therapy
100%
Krukenberg Tumor
100%
Bevacizumab
100%
Diseases
100%
Ovarian Cancer
33%
Gastrointestinal Perforation
33%
Progression Free Survival
16%
Prospective Study
16%
Progressive Disease
16%
Fluorouracil
16%
Doxorubicin
16%
Cyclophosphamide
16%
Tumor Antigen
16%
Cytotoxic Chemotherapy
16%
Docetaxel
16%
Endothelial Cell Growth Factor
16%
Chylous Ascites
16%
Cytotoxic Agent
16%
Pharmacology, Toxicology and Pharmaceutical Science
Combination Therapy
100%
Bevacizumab
100%
Ovary Carcinoma
100%
Diseases
100%
Ovary Cancer
28%
Digestive System Perforation
28%
Progression Free Survival
14%
Prospective Study
14%
Doxorubicin
14%
Cyclophosphamide
14%
Fluorouracil
14%
Tumor Antigen
14%
Cytotoxic Chemotherapy
14%
Docetaxel
14%
Endothelial Cell Growth Factor
14%
Chylous Ascites
14%
Cytotoxic Agent
14%
Immunology and Microbiology
Bevacizumab
100%
Tumor Antigen
25%
Progression Free Survival
25%
Cyclophosphamide
25%
Endothelial Cell Growth Factor
25%